Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Sexual adverse events

Silodosin probably leads to higher sexual adverse events compared with tamsulosin (moderate certainty).

1 finding from 1 review

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
RR 6.05 [3.55, 10.31]
10 studies · 1849 participants
Moderate

Sexual adverse events

Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).

1 finding from 1 review

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
RR 5.93 [2.16, 16.29]
4 studies · 405 participants
Moderate

Sexual adverse events

Silodosin probably leads to higher sexual adverse events compared with alfuzosin (moderate certainty).

1 finding from 1 review

Sexual adverse events

Silodosin probably leads to higher sexual adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
RR 26.07 [12.36, 54.97]
4 studies · 1967 participants
Moderate

Sexual adverse events

Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).

1 finding from 1 review